early diagnosis of alzheimer’s disease with blood test; tempting but challenging

The increasing prevalence of alzheimer’s disease (ad) has led to a health crisis. according to official statistics, more than 55 million people globally have ad or other types of dementia, making it the sixth leading cause of death. it is still difficult to diagnose ad and there is no definitive diagnosis yet; post-mortem autopsy is still the only definite method. moreover, clinical manifestations occur very late in the course of disease progression; therefore, profound irreversible changes have already occurred when the disease manifests. studies have shown that in the preclinical stage of ad, changes in some biomarkers are measurable prior to any neurological damage or other symptoms. hence, creating a reliable, fast, and affordable method capable of detecting ad in early stage has attracted the most attention. seeking clinically applicable, inexpensive, less invasive, and much more easily accessible biomarkers for early diagnosis of ad, blood-based biomarkers (bbbs) seem to be an ideal option. this review is an inclusive report of bbbs that have been shown to be altered in the course of ad progression. the aim of this report is to provide comprehensive insight into the research status of early detection of ad based on bbbs.